Immatics (IMTX) Share-based Compensation (2019 - 2026)
Immatics (IMTX) posted Share-based Compensation of $3.8 million for Q4 2025, up 1.48% sequentially from $3.8 million in Q3 2025, and down 20.57% YoY from $4.8 million in Q4 2024.
Analysis
Immatics (IMTX) Share-based Compensation (2019 - 2026) Analysis & Trends
Immatics has reported Share-based Compensation for 7 years, with the latest figure at $3.8 million in Q4 2025.
- Quarterly Share-based Compensation fell 20.57% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.9 million (down 11.63% YoY) and the FY2025 annual result came in at $17.0 million, down 11.16% from the prior year.
- Share-based Compensation rose to $3.8 million in Q4 2025 per IMTX's latest filing, from $3.8 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $10.0 million in Q1 2021 and troughed at -$17.5 million in Q4 2023.
- A 5-year average of $4.6 million and a median of $5.3 million in 2021 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2023: Share-based Compensation surged 108769.42% in 2021, then plunged 393.7% in 2023.
- Over 5 years, Share-based Compensation stood at $5.4 million in 2021, then advanced by 10.16% to $6.0 million in 2022, then slumped by 393.7% to -$17.5 million in 2023, then soared by 127.64% to $4.8 million in 2024, then retreated by 20.57% to $3.8 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3.8 million, $3.8 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -8.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.33 Mn |
| Mar 31, 2026 | 6.92 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 14.02 Mn |
| Jun 30, 2025 | -5.21 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 4.84 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 4.64 Mn |
| Mar 31, 2024 | 4.67 Mn |
| Dec 31, 2023 | 21.57 Mn |
| Sep 30, 2023 | -116,479.18 |
| Jun 30, 2023 | 578,218.85 |
| Mar 31, 2023 | 251,161.99 |
| Dec 31, 2022 | 29.68 Mn |
| Sep 30, 2022 | -17.93 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Mar 31, 2022 | 6.40 Mn |
| Dec 31, 2021 | 30.65 Mn |
| Sep 30, 2021 | -19.65 Mn |